[22961] A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase 2 study to investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with atrial fibrillation.

Condition studied

Atrial fibrillation

Investigational medicinal product(s)

Eligibility

Primary endpoint

Participants with conversion from atrial fibrillation (AF) to sinus rhythm (SR), sustained for ≥1 minute, within 3 hours after start of study intervention administration, and prior to use of rescue therapy or other SoC for cardioversion

Endpoint detail

Participants who experienced Treatment Emergent Adverse Events (TEAE)s, Time to conversion from AF to SR as defined in the primary endpoint, Participants in SR, at 3 hours after start of study intervention administration without prior use of rescue therapy or other SoC for cardioversion, Plasma concentration of BAY 3670549 at the end of the infusion